Literature DB >> 27695585

Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.

Gregory W Hosier1, Matthew T Roberts2.   

Abstract

Entities:  

Year:  2016        PMID： 27695585      PMCID： PMC5028215          DOI： 10.5489/cuaj.3652

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  16 in total

1.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

2.  Lack of KRAS and BRAF mutation in renal cell carcinoma.

Authors:  S Gattenlöhner; B Etschmann; H Riedmiller; H-K Müller-Hermelink
Journal:  Eur Urol       Date:  2009-02-28       Impact factor: 20.096

3.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

Review 4.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Authors:  Matthew Holderfield; Marian M Deuker; Frank McCormick; Martin McMahon
Journal:  Nat Rev Cancer       Date:  2014-07       Impact factor: 60.716

5.  Familial renal cell carcinoma from the Swedish Family-Cancer Database.

Authors:  Hao Liu; Jan Sundquist; Kari Hemminki
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

Review 6.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

Review 7.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Authors:  Andrew G Renehan; Margaret Tyson; Matthias Egger; Richard F Heller; Marcel Zwahlen
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

Review 9.  Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.

Authors:  Peter Kar Han Lau; Paolo A Ascierto; Grant McArthur
Journal:  Curr Opin Immunol       Date:  2016-01-05       Impact factor: 7.486

10.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.